Peter Welch (D-VT)

ETHIC Act

S. 2276 · Senate bill Commerce

A Democratic bill with 1 Republican cosponsor · See all 2 cosponsors

Last activity — Read twice and referred to the Committee on the Judiciary.

In committee

Introduced and handed to a committee in the chamber it started in.

The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.

Its path through Congress

  1. Introduced
  2. In Committee

What this bill would do

The ETHIC Act aims to address patent thickets. It proposes changes to title 35 of the United States Code regarding patent infringement actions. Under this bill, a person bringing an infringement action against certain parties can assert no more than one patent per Patent Group. This limit applies to those involved with specific drug applications or biological product licensures. The Act also defines a Patent Group based on the use of disclaimers to avoid obviousness-type double patenting.

Yes· 3 of 6

  • Scored +6

    Does this lower the price of prescription medicines?

    The act aims to curb patent thickets that often delay the entry of cheaper generic or biological competitors.

  • Scored +5

    Would households on low incomes be better off under this?

    Lowering prescription drug costs through competition benefits low-income households.

  • Scored +5

    Would retired people be better off under this?

    Seniors often rely on more medication and could benefit from lower prescription drug costs.

The opposite

  • Scored -3

    Would business owners be better off under this?

    Patent holders may find their ability to defend their intellectual property through multiple filings restricted.